Clinical trials: Diffuse Parenchymal Lung Diseases
Pulmonary Fibrosis
LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION
Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after…
- Trial name
- INC-CVD-202001 (NCT04409275)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Connective Tissue Disease-associated Interstitial Lung Disease, Interstitial Lung Disease
Telemonitoring of Treatment Effects in Connective Tissue Disease-associated Interstitial Lung Disease (TEL-CTD-ILD)
1. Impact of telemonitoring on quality of life (QoL) of patients with CTD-ILD 2. Evaluation of health status of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) using telemonitoring and…
- Conditions
- Connective Tissue Disease-associated Interstitial Lung Disease, Interstitial Lung Disease, Connective Tissue Diseases
- Trial name
- TEL-CTD-ILD (NCT04428957)
- Testing
- Telemonitoring
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Lodz
Pulmonary Sarcoidosis
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
A study of XTMAB-16 in patients with pulmonary sarcoidosis
- Trial name
- NCT07680166
- Testing
- XTMAB-16
- Volunteers
- 182 people
- Sponsor
- Xentria, Inc.
Pulmonary Hypertension
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo
- Trial name
- NCT05176951
- Testing
- Treprostinil Palmitil
- Where
- 25 sites in Argentina, Australia and 5 more
- Volunteers
- 39 people
- Sponsor
- Insmed Incorporated
Wegener's Granulomatosis, Churg-Strauss Syndrome
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis
- Trial name
- NCT00307593
- Testing
- Infliximab, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Interstitial Lung Disease, Pulmonary Rehabilitation
Physiological Effects of HFNC During Exercise in Patients With Fibrosing Interstitial Lung Diseases
in this study, the investigators aim to describe the effects of highflow nasal canulae oxygen therapy (HFNC) on respiratory muscle function during exercise in patients with fibrosing interstitial lung diseases (ILD) during an…
- Trial name
- HighFlowMusc (NCT05372926)
- Testing
- high flow nasal canulae, Ventury mask
- Where
- France
- Volunteers
- 16 people
- Sponsor
- ADIR Association
Idiopathic Pulmonary Fibrosis
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized…
- Trial name
- NCT02688647
- Testing
- Belumosudil, BSC
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Kadmon Corporation, LLC
Mediastinal Lymphadenopathy, Mediastinal Lesions
Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy
Transbronchial cryobiopsy is a relatively recent technique, increasingly used for the diagnosis of various respiratory diseases, including neoplasms, diffuse interstitial lung diseases (ILDs), and rejection after lung…
- Conditions
- Mediastinal Lymphadenopathy, Mediastinal Lesions, Diffuse Interstitial Lung Diseases
- Trial name
- SeReCryo (NCT07301697)
- Testing
- performance of a transbronchial cryobiopsy or EBUS-cryobiopsy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of…
- Trial name
- NCT04968574
- Testing
- taladegib
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Endeavor Biomedicines, Inc.
Interstitial Lung Disease
The Six Minute Walk Test: Influence of Instruction on Results
Two - four 6MWT performed according to ATS standards. Each walk however had specifically altered wording and coaching performed in random order to determine differences in outcomes. One walk was done in the standard ATS fashion.
- Trial name
- NCT01789996
- Testing
- alternative six minute walk test, Standard six minute walk test
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Inova Health Care Services
Idiopathic Inflammatory Myopathy, Interstitial Lung Disease
Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells
Interstitial lung disease (ILD) is a common pulmonary manifestation of idiopathic inflammatory myopathy (IIM). The overall 5-year mortality is 50%.
- Trial name
- NCT05129410
- Testing
- Mycophenolate Mofetil
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Interstitial Lung Disease With Systemic Sclerosis
Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous multisystem disease characterized by vascular dysfunction, immune abnormalities, and progressive fibrosis of the skin and internal organs.
- Trial name
- NCT07817160
- Testing
- Pelvic Floor Health Knowledge Assessment, Pelvic Floor Dysfunction Assessment, Core Endurance Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Biruni University
Idiopathic Pulmonary Fibrosis
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier.
- Trial name
- MAVRIC (NCT07520110)
- Testing
- Metformin
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Massachusetts, Worcester
Hypersensitivity Pneumonitis
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
- Trial name
- PREDICT-HP (NCT04844359)
- Where
- 7 sites in United States
- Volunteers
- 137 people
- Sponsor
- National Jewish Health
Pulmonary Hypertension Due to Lung Diseases
Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
This observational real-world study aims to evaluate the longitudinal clinical outcomes of adult patients with Group 3 pulmonary hypertension (PH), associated with chronic lung diseases such as interstitial lung disease, who are…
- Trial name
- AirFly (NCT07478094)
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Fibrosis
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial…
- Trial name
- NCT01417156
- Testing
- Nintedanib, Pirfenidoneone
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Pulmonary, Lung Diseases, Interstitial
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
- Trial name
- EFS (NCT05867914)
- Testing
- Inhaled Nitric Oxide (iNO)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Third Pole Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Pneumothorax, Pulmonary Fibrosis
Computerized Lung Sound Analysis
This clinical trial is conducted within the research project 'Computerized Lung Sound Analysis'. The research goal is the development of a system enabling the automatic classification of lung sounds, which will result in a…
- Trial name
- CLSA (NCT02771184)
- Testing
- Lung Sound Recording System
- Where
- Austria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Smolle-Juettner Freyja, Prof MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.